Special Offer: Get 50% off your first 2 months when you do one of the following
Personalized offer codes will be given in each session
Starts Here in d, hrs, min, s
In this webinar, you will discover how the adoption of the SOPHiA DDM™ platform in combination with Microsoft Azure enables accurate analysis of complex genomics data and reduces the burden of building and maintaining IT infrastructures. This comb...
  • Wednesday, September 15, 2021 · 11:00 AM EDT
    SOPHiA DDM™ enables real-time SARS-CoV-2 surveillance, enabling the detection of new and emerging strains with high accuracy and confidence. Furthermore, as vaccination efforts improve around the globe, the use of SOPHiA DDM™ provides access to ne...
  • Blank-1
    This corporate satellite was presented live at ESHG 2021 on August 28th, 2021.

    Next-Generation Sequencing (NGS) is rapidly improving research efforts for rare and inherited diseases. The adoption of exome sequencing helps determine the variations...
  • Blank-3
    This talk was presented at CGC 2021 on August 2nd, 2021. Join our experts to learn more about how the SOPHiA DDMTM platform supports solid tumor detection.
  • Tuesday, June 22, 2021 · 11:00 AM EDT
    Hereditary cancer syndromes are a set of complex diseases, often presenting with diverse clinical phenotypes, involving multiple genes of interest with variable penetrance. Large scale genomic sequencing of multi-gene panels has become the standar...
  • Blank-6
    SOPHiA GENETICS has demonstrated a proof of concept for real time global variant surveillance of spike protein mutations through the SOPHiA GENETICS' secured peer-network and compared findings to the GISAID timeline. Paragon Genomics SARS-CoV-2 pa...
  • Blank-5
    The rate of SARS-CoV-2 transmission continues to challenge the community's ability to monitor and control the spread of COVID-19. In this discussion, our expert will share insights on the different approaches to monitor viral genome sequences and ...
  • On-Demand
    Over the last decade, whole-exome sequencing has emerged as a comprehensive and cost-effective tool for researching rare disease-causing variants, including copy number variants (CNVs). As a result, researchers can gain extensive, valuable informa...
  • On-Demand
    This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.  

    Molecular profiling by next...
  • On-Demand
    This webinar discusses how the University of Michigan has implemented a new next-generation sequencing (NGS) capture-based solution to assess myeloid malignancies while minimizing required laboratory resources.

    The evolution of molecular oncolog...
  • Blank-3
    Las variaciones en el número de copias (CNV) del ADN son una causa bien documentada de enfermedad genética humana. La detección de CNV es un reto ya que las soluciones analíticas deben alcanzar una resolución a nivel de exón para ofrecer resultado...
  • On-Demand
    This scientific evidence-webinar will discuss Genotypos Science Labs’ experience with a whole exome sequencing solution, supporting the detection of copy number variants for the management of a complex cases. DNA copy number variations (CNVs) are ...
SOPHiA GENETICS is a health tech company democratizing Data-Driven Medicine to improve health outcomes and economics worldwide. By unlocking the power of new-generation health data for cancer and rare diseases management, the universal SOPHiA DDM Platform allows clinical researchers to act with precision and confidence. The company’s innovative approach enables an ever-expanding community of over 1,000 institutions to benefit from knowledge sharing, fostering a new era in healthcare. SOPHiA GENETICS’s achievement is recognized by the MIT Technology Review’s "50 Smartest Companies".